Article
"Fibromyalgianess" is highlighted as a risk factor for undue, extended glucocorticoid use in rheumatoid arthritis (RA) patients, according to Wallace and colleagues in Rheumatology.
All News
Article
How much psoriasis do you need to have in order to have psoriatic arthritis? This plus a review of rheumatology and COVID news from the past week on RheumNow.com.
Article
Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.
Dr. John Cush
Tweet
Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.
https://t.co/Uu1VjAbKMi https://t.co/uGvTyLExjf
Dr. John Cush
Tweet
The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs).
https://t.co/RNWrLR53Wx https://t.co/mMmKKrX9vx
Dr. John Cush
Tweet
Health personnel (HCP) @ long-term care facilities (LTCFs) are at high risk for COVID-19. March 2021, 57% of LTCF HCPs were vaccinated. COVID-19 vax was highest in MDs (75.1%); lowest nurses (56.7%) & aides (45.6%). https://t.co/VjHutcrh26 https://t.co/8aO1mFgC8f
Dr. John Cush
Tweet
ICYMI: The FDA has authorized baricitinib ALONE as treatment for COVID-19 hospitalized adults and pediatric patients requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) https://t.co/WMc78GmOLU https://t.co/Bp5tL4pRk5
Dr. John Cush
Tweet
Worth another share--
Turning the Corner on CV Risk in Rheumatoid Arthritis by Richard Conway ( @RichardPAConway) #EULAR2021
https://t.co/S0ownscRKv https://t.co/7QtynRKAd6
Dr. John Cush
Tweet
ICYMI: One of our top June videos
WATCH: Is blindness with Tocilizumab in GCA a worry?
Dr. David Liew ( @drdavidliew ) weighs in. #EULAR2021
https://t.co/eFrmbkW9Gy https://t.co/4tY3hEDj2j
Dr. John Cush
Tweet
Pain Persists in RA, Even Without Inflammation
One-third of patients with rheumatoid arthritis had unacceptably high levels of pain 5 years after diagnosis, often despite low levels of inflammation, Swedish researchers found.
https://t.co/K8zf1pE9jM https://t.co/aEBu7jVHft
Dr. John Cush
Tweet
RheumNow Podcast – Psoriatic Arthritis Without Psoriasis
Download wherever you get your podcasts!
https://t.co/Ra5f7507XT https://t.co/5WqPCgGVpr
Dr. John Cush
Tweet
Did you see this tweet from May? Worth re-sharing.
Rituximab Tops Mycophenolate Mofetil for Pemphigus Vulgaris. One year study of 135 moderate-to-severe pemphigus patients saw complete remission in 40% of RTX vs 10% of MMF patients. https://t.co/yAauFRjHCe https://t.co/bibHXaHtWf
Dr. John Cush
Tweet
ICYMI: Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis https://t.co/Twbe1ClT5w
Dr. John Cush
Tweet
New podcast available for download! We focus on the articles shared this week on https://t.co/V10S4oVFsv .
https://t.co/Ra5f7507XT https://t.co/Pz0RFxLIOx
Dr. John Cush
Tweet
Swiss SCQM registry compared 3217 RA & 819 PsA pts; PsA had more obese (36.5% overweight, 23.8% obese) than RA (4.4% underweight, 31.8% overweight, 17.0% obese). Obese PsA had higher CRP, Dz activity, worse QOL, pain & skin https://t.co/UzbKlT3tSz
Dr. John Cush
Tweet
Literature review examined safety of IL-17 inhibitors in 106 controlled RCTs, 40,053 pts. Inflammatory bowel disease was reported in 0.4% of IL-17i Rx patients. (same in 61 uncontrolled RCTs -0.36%). Other AE: diarrhea (2.5%), N/V(0.7%) https://t.co/2wSZQqB1Zs
Dr. John Cush
Tweet
JAMA article on using new features in Updated PubMed:
1) Focus the Clinical Question
2) Use PubMed Clinical Query Filters
3) Refine the Search Terms
https://t.co/ExK8p2hVnX
Dr. John Cush
Tweet
Comparison of 1040 elderly-onset RA (EORA) and 710 non-EORA patients showed similar disease activity, DMARD choices, drug response rates and reasons for Rx discontinuation - There's no reason EORA shouldn't be treated as aggressive as all RA! https://t.co/P2gpPlJVZE
Dr. John Cush
Tweet
ICYMI:
Drugs capable of inducing drug-associated ANCA vasculitis - mirabegron (Myrbetriq), sofosbuvir (Sovaldi, antiviral), nintedanib (Ofev), hydralazine, propylthiouracil, thiamazole, minocycline, carbimazole, allopurinol, influenza vax.... https://t.co/KhK2w0IGAx
Dr. John Cush
Tweet
Health personnel (HCP) @ long-term care facilities (LTCFs) are at high risk for COVID-19. March 2021, 57% of LTCF HCPs were vaccinated. COVID-19 vax was highest in MDs (75.1%); lowest nurses (56.7%) & aides (45.6%). https://t.co/VjHutcrh26
